Who makes BW-1010: 50 µg - pipette - IN?

BW-1010: 50 µg - pipette - IN is developed by BlueWillow Biologics.

What development phase is BW-1010: 50 µg - pipette - IN in?

BW-1010: 50 µg - pipette - IN is in Phase 1.

Last reviewed 2026-04-19 · How we verify

BW-1010: 50 µg - pipette - IN

BlueWillow Biologics · Phase 1 active Biologic

At a glance

Generic name	BW-1010: 50 µg - pipette - IN
Sponsor	BlueWillow Biologics
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BW-1010: 50 µg - pipette - IN CI brief — competitive landscape report
BW-1010: 50 µg - pipette - IN updates RSS · CI watch RSS
BlueWillow Biologics portfolio CI